A4M 2026 Exam | A4M001 Endocrinology,
Cardiology & Neurology Questions &
Answers | Study Guide
A4M 2026 EXAM | A4M001 ENDOCRINOLOGY, CARDIOLOGY & NEUROLOGY
STUDY GUIDE
DOCUMENT OVERVIEW
• Comprehensive question practice exam designed to reinforce clinical knowledge
and prepare for board certification; features clinical vignettes, evidence-based
scenarios, and high-yield content across three core domains of anti-aging medicine
• Study strategy: Review each question carefully, attempt to answer before checking
the correct response, and use rationales to identify knowledge gaps and reinforce
pathophysiology, diagnostic criteria, and clinical management principles
ENDOCRINOLOGY SECTION (Questions 1-70)
1. A 54-year-old male presents with progressive fatigue, weight gain, and cold
intolerance over six months. Laboratory findings show TSH 8.2 mIU/L and free
T4 2.8 ng/dL. What is the primary pathophysiologic process occurring in this
patient?
A) Excessive thyroid hormone production by thyroid follicular cells
B) Increased conversion of T4 to reverse T3 in peripheral tissues
C) Inadequate production and secretion of thyroid hormones from the thyroid
gland
D) Antibody-mediated destruction of the anterior pituitary gland
E) Thyroid hormone receptor resistance at the cellular level
✓ CORRECT ANSWER: C) Inadequate production and secretion of thyroid
hormones from the thyroid gland
,RATIONALE: The patient presents with classic hypothyroid symptoms (fatigue,
weight gain, cold intolerance) and laboratory evidence of primary hypothyroidism:
elevated TSH (8.2 mIU/L, normal <4.5) and low-normal free T4 (2.8 ng/dL, normal
4.5-12). The elevated TSH represents appropriate pituitary response to insufficient
circulating thyroid hormone, confirming primary thyroid gland failure. This pattern
is diagnostic of primary hypothyroidism, most commonly caused by Hashimoto's
thyroiditis in iodine-sufficient regions. Options B, D, and E represent alternative
endocrine pathologies that would produce different laboratory patterns. Option A
describes hyperthyroidism, the opposite disorder.
2. A 62-year-old postmenopausal woman with osteoporosis is found to have
serum calcium 9.8 mg/dL, phosphate 2.1 mg/dL, PTH 142 pg/mL, and 25-OH
vitamin D 18 ng/mL. Which diagnosis best explains these findings?
A) Primary hyperparathyroidism with vitamin D insufficiency
B) Secondary hyperparathyroidism from vitamin D deficiency
C) Tertiary hyperparathyroidism from chronic kidney disease
D) Familial hypocalciuric hypercalcemia
E) Vitamin D-resistant rickets
✓ CORRECT ANSWER: B) Secondary hyperparathyroidism from vitamin D
deficiency
RATIONALE: The key finding is low-normal serum calcium (9.8 mg/dL) with elevated
PTH (142 pg/mL) and critically low vitamin D (18 ng/mL, normal >30). In secondary
hyperparathyroidism from vitamin D deficiency, low vitamin D causes decreased
intestinal calcium absorption, leading to hypocalcemia that stimulates appropriate
PTH elevation. Primary hyperparathyroidism (Option A) presents with
hypercalcemia, not normal-low calcium. Tertiary hyperparathyroidism (Option C)
develops after prolonged secondary hyperparathyroidism in renal failure, with
autonomous PTH production. Familial hypocalciuric hypercalcemia (Option D)
presents with hypercalcemia and inappropriately low PTH. The clinical picture is
consistent with age-related vitamin D insufficiency and secondary PTH response.
,3. A 48-year-old male with newly diagnosed type 2 diabetes (HbA1c 8.4%)
presents for anti-aging medicine evaluation. Physical examination reveals
central obesity, blood pressure 138/88 mmHg, and acanthosis nigricans on the
neck. What is the underlying metabolic abnormality linking these findings?
A) Excessive glucagon secretion from pancreatic alpha cells
B) Insulin resistance at the cellular level with compensatory hyperinsulinemia
C) Autoimmune destruction of pancreatic beta cells
D) Increased hepatic glucose production from gluconeogenesis alone
E) Defective incretin hormone secretion by enteroendocrine cells
✓ CORRECT ANSWER: B) Insulin resistance at the cellular level with
compensatory hyperinsulinemia
RATIONALE: The patient demonstrates classic features of insulin resistance
syndrome: central obesity, hypertension, impaired glucose tolerance, and
acanthosis nigricans (a cutaneous marker of hyperinsulinemia). Insulin resistance
reduces cellular glucose uptake, requiring excessive insulin secretion to maintain
euglycemia initially; this compensatory hyperinsulinemia drives sodium retention
(hypertension), visceral adiposity accumulation, and skin manifestations. Type 2
diabetes occurs when beta cells eventually fail to maintain sufficient
hyperinsulinemia. Option A describes type 1 diabetes pathophysiology. Option C
represents autoimmune beta cell destruction. Option D describes one consequence
but not the primary abnormality. Option E describes a mechanism relevant in some
cases but not the unifying pathology.
4. A 71-year-old woman with hypogonadism is started on hormone
replacement therapy. Baseline testicular volume is 12 mL bilaterally. After
three months of therapy, you notice gynecomastia development and mild
elevation in liver enzymes. What is the most likely explanation?
A) Testosterone conversion to estradiol via aromatase enzyme activity
, B) Direct estrogenic effect of exogenous testosterone preparations
C) Suppression of follicle-stimulating hormone with unopposed luteinizing
hormone activity
D) Hepatotoxic effects of the testosterone ester carrier molecule
E) Primary hypothyroidism induced by testosterone therapy
✓ CORRECT ANSWER: A) Testosterone conversion to estradiol via aromatase
enzyme activity
RATIONALE: Elevated estradiol from peripheral aromatization of excess
testosterone is the primary cause of gynecomastia in testosterone replacement
therapy. In older men with increased adipose tissue (aromatase-rich tissue),
supraphysiologic testosterone doses undergo enhanced conversion to estradiol.
The development of gynecomastia indicates relative estrogen excess requiring
either dose adjustment or concurrent aromatase inhibitor administration. Liver
enzyme elevation may reflect increased hepatic processing of testosterone and its
metabolites, not direct hepatotoxicity. Options B, D, and E do not account for the
specific clinical presentation. Option C describes hypothalamic-pituitary
suppression but does not explain gynecomastia pathogenesis.
5. A 56-year-old male with metabolic syndrome is found to have fasting
glucose 156 mg/dL, triglycerides 385 mg/dL, HDL cholesterol 32 mg/dL, and
normal LDL cholesterol. What is the primary metabolic driver of this
dyslipidemia pattern?
A) Increased VLDL production from the liver due to hepatic insulin resistance
B) Decreased lipoprotein lipase activity in adipose tissue
C) Enhanced cholesterol absorption in the terminal ileum
D) Reduced apolipoprotein B synthesis by enterocytes
E) Increased peripheral tissue uptake of triglyceride-rich lipoproteins
Cardiology & Neurology Questions &
Answers | Study Guide
A4M 2026 EXAM | A4M001 ENDOCRINOLOGY, CARDIOLOGY & NEUROLOGY
STUDY GUIDE
DOCUMENT OVERVIEW
• Comprehensive question practice exam designed to reinforce clinical knowledge
and prepare for board certification; features clinical vignettes, evidence-based
scenarios, and high-yield content across three core domains of anti-aging medicine
• Study strategy: Review each question carefully, attempt to answer before checking
the correct response, and use rationales to identify knowledge gaps and reinforce
pathophysiology, diagnostic criteria, and clinical management principles
ENDOCRINOLOGY SECTION (Questions 1-70)
1. A 54-year-old male presents with progressive fatigue, weight gain, and cold
intolerance over six months. Laboratory findings show TSH 8.2 mIU/L and free
T4 2.8 ng/dL. What is the primary pathophysiologic process occurring in this
patient?
A) Excessive thyroid hormone production by thyroid follicular cells
B) Increased conversion of T4 to reverse T3 in peripheral tissues
C) Inadequate production and secretion of thyroid hormones from the thyroid
gland
D) Antibody-mediated destruction of the anterior pituitary gland
E) Thyroid hormone receptor resistance at the cellular level
✓ CORRECT ANSWER: C) Inadequate production and secretion of thyroid
hormones from the thyroid gland
,RATIONALE: The patient presents with classic hypothyroid symptoms (fatigue,
weight gain, cold intolerance) and laboratory evidence of primary hypothyroidism:
elevated TSH (8.2 mIU/L, normal <4.5) and low-normal free T4 (2.8 ng/dL, normal
4.5-12). The elevated TSH represents appropriate pituitary response to insufficient
circulating thyroid hormone, confirming primary thyroid gland failure. This pattern
is diagnostic of primary hypothyroidism, most commonly caused by Hashimoto's
thyroiditis in iodine-sufficient regions. Options B, D, and E represent alternative
endocrine pathologies that would produce different laboratory patterns. Option A
describes hyperthyroidism, the opposite disorder.
2. A 62-year-old postmenopausal woman with osteoporosis is found to have
serum calcium 9.8 mg/dL, phosphate 2.1 mg/dL, PTH 142 pg/mL, and 25-OH
vitamin D 18 ng/mL. Which diagnosis best explains these findings?
A) Primary hyperparathyroidism with vitamin D insufficiency
B) Secondary hyperparathyroidism from vitamin D deficiency
C) Tertiary hyperparathyroidism from chronic kidney disease
D) Familial hypocalciuric hypercalcemia
E) Vitamin D-resistant rickets
✓ CORRECT ANSWER: B) Secondary hyperparathyroidism from vitamin D
deficiency
RATIONALE: The key finding is low-normal serum calcium (9.8 mg/dL) with elevated
PTH (142 pg/mL) and critically low vitamin D (18 ng/mL, normal >30). In secondary
hyperparathyroidism from vitamin D deficiency, low vitamin D causes decreased
intestinal calcium absorption, leading to hypocalcemia that stimulates appropriate
PTH elevation. Primary hyperparathyroidism (Option A) presents with
hypercalcemia, not normal-low calcium. Tertiary hyperparathyroidism (Option C)
develops after prolonged secondary hyperparathyroidism in renal failure, with
autonomous PTH production. Familial hypocalciuric hypercalcemia (Option D)
presents with hypercalcemia and inappropriately low PTH. The clinical picture is
consistent with age-related vitamin D insufficiency and secondary PTH response.
,3. A 48-year-old male with newly diagnosed type 2 diabetes (HbA1c 8.4%)
presents for anti-aging medicine evaluation. Physical examination reveals
central obesity, blood pressure 138/88 mmHg, and acanthosis nigricans on the
neck. What is the underlying metabolic abnormality linking these findings?
A) Excessive glucagon secretion from pancreatic alpha cells
B) Insulin resistance at the cellular level with compensatory hyperinsulinemia
C) Autoimmune destruction of pancreatic beta cells
D) Increased hepatic glucose production from gluconeogenesis alone
E) Defective incretin hormone secretion by enteroendocrine cells
✓ CORRECT ANSWER: B) Insulin resistance at the cellular level with
compensatory hyperinsulinemia
RATIONALE: The patient demonstrates classic features of insulin resistance
syndrome: central obesity, hypertension, impaired glucose tolerance, and
acanthosis nigricans (a cutaneous marker of hyperinsulinemia). Insulin resistance
reduces cellular glucose uptake, requiring excessive insulin secretion to maintain
euglycemia initially; this compensatory hyperinsulinemia drives sodium retention
(hypertension), visceral adiposity accumulation, and skin manifestations. Type 2
diabetes occurs when beta cells eventually fail to maintain sufficient
hyperinsulinemia. Option A describes type 1 diabetes pathophysiology. Option C
represents autoimmune beta cell destruction. Option D describes one consequence
but not the primary abnormality. Option E describes a mechanism relevant in some
cases but not the unifying pathology.
4. A 71-year-old woman with hypogonadism is started on hormone
replacement therapy. Baseline testicular volume is 12 mL bilaterally. After
three months of therapy, you notice gynecomastia development and mild
elevation in liver enzymes. What is the most likely explanation?
A) Testosterone conversion to estradiol via aromatase enzyme activity
, B) Direct estrogenic effect of exogenous testosterone preparations
C) Suppression of follicle-stimulating hormone with unopposed luteinizing
hormone activity
D) Hepatotoxic effects of the testosterone ester carrier molecule
E) Primary hypothyroidism induced by testosterone therapy
✓ CORRECT ANSWER: A) Testosterone conversion to estradiol via aromatase
enzyme activity
RATIONALE: Elevated estradiol from peripheral aromatization of excess
testosterone is the primary cause of gynecomastia in testosterone replacement
therapy. In older men with increased adipose tissue (aromatase-rich tissue),
supraphysiologic testosterone doses undergo enhanced conversion to estradiol.
The development of gynecomastia indicates relative estrogen excess requiring
either dose adjustment or concurrent aromatase inhibitor administration. Liver
enzyme elevation may reflect increased hepatic processing of testosterone and its
metabolites, not direct hepatotoxicity. Options B, D, and E do not account for the
specific clinical presentation. Option C describes hypothalamic-pituitary
suppression but does not explain gynecomastia pathogenesis.
5. A 56-year-old male with metabolic syndrome is found to have fasting
glucose 156 mg/dL, triglycerides 385 mg/dL, HDL cholesterol 32 mg/dL, and
normal LDL cholesterol. What is the primary metabolic driver of this
dyslipidemia pattern?
A) Increased VLDL production from the liver due to hepatic insulin resistance
B) Decreased lipoprotein lipase activity in adipose tissue
C) Enhanced cholesterol absorption in the terminal ileum
D) Reduced apolipoprotein B synthesis by enterocytes
E) Increased peripheral tissue uptake of triglyceride-rich lipoproteins
